Biogen, Array strike preclinical autoimmune disease pact

Array BioPharma ($ARRY) has formed a drug discovery pact with Biogen Idec ($BIIB) to develop inhibitors targeting a novel kinase for the treatment of autoimmune disorders. The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform. Under the terms of the agreement, Biogen will be responsible for all aspects of clinical development and commercialization and fund three years of research. More